Share on LinkedInShare on LinkedIn

ARTICLE · 21 MAY 2026

Dormant DINs Revisited: MFN Pricing And The Evolving Impacts On Canada’s Patent Linkage Regime

Developments since then, including renewed U.S. attention to most‑favored‑nation (“MFN”) drug pricing have heightened the legal and policy concerns associated with that notice. In our view, those concerns merit renewed scrutiny.

CanadaIntellectual Property

On January 26, 2024, Health Canada issued a notice clarifying that drugs with a “dormant” Drug Identification Number (“DIN”) may not be considered “marketed” for the purposes of the Patented Medicines (Notice of Compliance) Regulations (the “PM(NOC) Regulations”). In our first bulletin on the subject, we reviewed the consequences of that position for innovators relying on Canada’s patent linkage framework to protect their innovative medicines.

Developments since then, including renewed U.S. attention to most‑favored‑nation (“MFN”) drug pricing have heightened the legal and policy concerns associated with that notice. In our view, those concerns merit renewed scrutiny.

A Brief Recap: Dormant DINs and PM(NOC) Protection

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from